Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 105171118 | 10517111 | 8 | F | 20090929 | 20160921 | 20141014 | 20160928 | EXP | AU-ABBVIE-14P-008-1259583-00 | ABBVIE | 67.77 | YR | M | Y | 85.00000 | KG | 20160927 | MD | AU | AU |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 105171118 | 10517111 | 1 | PS | HUMIRA | ADALIMUMAB | 1 | Subcutaneous | Y | U | UNKNOWN | 125057 | 40 | MG | SOLUTION FOR INJECTION | QOW | ||||
| 105171118 | 10517111 | 2 | SS | HUMIRA | ADALIMUMAB | 1 | Subcutaneous | Y | U | UNKNOWN | 125057 | 40 | MG | SOLUTION FOR INJECTION | QOW | ||||
| 105171118 | 10517111 | 3 | SS | HUMIRA | ADALIMUMAB | 1 | Subcutaneous | Y | U | UNKNOWN | 125057 | 40 | MG | SOLUTION FOR INJECTION | QOW | ||||
| 105171118 | 10517111 | 4 | C | EFFEXOR | VENLAFAXINE HYDROCHLORIDE | 1 | Oral | 0 | |||||||||||
| 105171118 | 10517111 | 5 | C | CADUET | AMLODIPINE BESYLATEATORVASTATIN CALCIUM | 1 | Oral | 10/40 | 0 | ||||||||||
| 105171118 | 10517111 | 6 | C | CADUET | AMLODIPINE BESYLATEATORVASTATIN CALCIUM | 1 | 0 | ||||||||||||
| 105171118 | 10517111 | 7 | C | DEPTRAN | DOXEPIN HYDROCHLORIDE | 1 | Oral | 0 | 100 | MG | |||||||||
| 105171118 | 10517111 | 8 | C | SPIRIVA | TIOTROPIUM BROMIDE MONOHYDRATE | 1 | 0 | ||||||||||||
| 105171118 | 10517111 | 9 | C | ONBREZ BREEZHALER | INDACATEROL | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 105171118 | 10517111 | 1 | Psoriasis |
| 105171118 | 10517111 | 4 | Depression |
| 105171118 | 10517111 | 5 | Hypertension |
| 105171118 | 10517111 | 6 | Hyperlipidaemia |
| 105171118 | 10517111 | 7 | Depression |
| 105171118 | 10517111 | 8 | Product used for unknown indication |
| 105171118 | 10517111 | 9 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 105171118 | 10517111 | OT |
| 105171118 | 10517111 | HO |
| 105171118 | 10517111 | LT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 105171118 | 10517111 | Alanine aminotransferase increased | |
| 105171118 | 10517111 | Aspartate aminotransferase increased | |
| 105171118 | 10517111 | Blood cholesterol decreased | |
| 105171118 | 10517111 | Blood glucose increased | |
| 105171118 | 10517111 | Blood triglycerides increased | |
| 105171118 | 10517111 | Gamma-glutamyltransferase increased | |
| 105171118 | 10517111 | Glomerular filtration rate decreased | |
| 105171118 | 10517111 | Injection site pain | |
| 105171118 | 10517111 | Nephrolithiasis | |
| 105171118 | 10517111 | Osteoarthritis | |
| 105171118 | 10517111 | Pneumonia | |
| 105171118 | 10517111 | Pyelonephritis | |
| 105171118 | 10517111 | Renal impairment |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 105171118 | 10517111 | 1 | 20090910 | 0 | ||
| 105171118 | 10517111 | 2 | 2011 | 201412 | 0 | |
| 105171118 | 10517111 | 3 | 201505 | 0 | ||
| 105171118 | 10517111 | 5 | 2011 | 0 |